 Recent immuno-oncology publications further confirm the Galectin Signature in cancer immunotherapy. In a rare and important combination of clinical effects, belapectin, Galectins galectin-3 inhibitor, we believe can both augment ICI or immune agonist therapy while simultaneously improving toxicitytolerability profiles. 